Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most core labeled claims are consistent (short-term ≤5 days, moderately severe acute opioid-level postoperative use/continuation after IV/IM, adult max 40 mg/day, and major boxed-warning risks). Several unsupported or potentially misleading claims are present (nasal spray availability; implied oral tablets initiated without IV/IM; opioid analgesia phrasing beyond label; speculative side effects; patent information and generic-market statements; and generalization that it is not recommended for chronic pain/pre-existing conditions beyond label).
Category Scores
Accurate Statements
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID).
Section 12 mechanism relates to prostaglandin synthetase inhibition; product class is NSAID.
Ketorolac is used for short-term pain management.
Section 1 and Boxed Warning: indicated for short-term (≤5 days in adults).
Ketorolac is used for moderate to severe acute pain that requires opioid analgesia.
Section 1: moderately severe acute pain that requires analgesia at the opioid level (usually postoperative).
Ketorolac is available in intramuscular injections.
Section 1/2: therapy should always be initiated with ketorolac tromethamine-IV or IM; tablets are continuation after IV/IM.
Ketorolac is available as intravenous solutions.
Section 1/2: therapy should always be initiated with ketorolac tromethamine-IV or IM.
The duration of use for ketorolac is limited to five days.
Section 1, Section 5, Boxed Warning: total combined duration not to exceed 5 days in adults.
Ketorolac carries risks of gastrointestinal bleeding.
Boxed Warning/Section 5: GI bleeding/ulceration/perforation risk.
Ketorolac carries risks of ulceration.
Boxed Warning/Section 5: GI ulceration risk.
Ketorolac carries risks of perforation.
Boxed Warning/Section 5: GI perforation risk.
Gastrointestinal bleeding, ulceration, and perforation associated with ketorolac can be serious and potentially fatal.
Section 5 GI Effects: can be serious and can be fatal.
Ketorolac can increase the risk of cardiovascular thrombotic events.
Section 5 Cardiovascular Effects: increased risk of serious CV thrombotic events, MI and stroke.
Ketorolac can increase the risk of myocardial infarction.
Section 5 Cardiovascular Effects: increased risk of myocardial infarction.
Ketorolac can increase the risk of stroke.
Section 5 Cardiovascular Effects: increased risk of stroke.
For oral administration, after an initial intramuscular or intravenous dose, the recommended adult dose is typically 10 mg every 4 to 6 hours as needed for pain.
Section 2: age 17–64 transition: 20 mg PO once then 10 mg q4–6h prn; label indicates max/day limits.
The maximum oral daily dose of ketorolac should not exceed 40 mg.
Section 2: not >40 mg/day; Boxed Warning notes daily maximum 40 mg in adults.
Ketorolac 10 mg tablets are prescribed for oral administration.
Drug / active ingredient is ketorolac tromethamine tablets (10 mg); Section 2 describes PO transition dosing.
Ketorolac 10 mg tablets are used to manage postoperative pain.
Section 1: usually in a postoperative setting; tablets are continuation therapy.
Ketorolac is considered a potent NSAID for acute pain.
Section 1 indicates efficacy in trials; label does not explicitly use the word 'potent' in provided excerpts, but acute analgesic use is supported.
Due to its risk profile, ketorolac is not typically recommended for chronic pain management.
Section 1/Boxed Warning: indicated only for short-term management; limitation to ≤5 days supports disfavoring chronic use (though phrasing 'not typically recommended' is not explicit).
Unsupported Statements
Ketorolac is available as nasal sprays.
Not supported by the provided labeling excerpts; label excerpts only reference IV/IM and tablets.
The 10 mg strength refers to the dosage of ketorolac in oral tablets.
Not explicitly confirmed in the supplied excerpts (though consistent with 'ketorolac tromethamine tablets (10 mg)'; confirmation of strength meaning is not shown in label text provided).
Ketorolac 10 mg tablets are prescribed for oral administration.
Partially supported (PO dosing exists), but the claim lacks the 'continuation only' restriction explicitly.
Ketorolac 10 mg tablets are used for other moderate to severe acute pain conditions.
Label excerpt specifies moderately severe acute pain requiring opioid-level analgesia, usually postoperative; 'other' acute pain conditions beyond postoperative setting is not specified.
Ketorolac carries risks of gastrointestinal bleeding, ulceration, and perforation associated with ketorolac can be serious and potentially fatal.
Overall supported for seriousness/fatality, but the 'potentially fatal' phrasing matches; this item is not truly unsupported—kept out of this list.
Other side effects of ketorolac may include dizziness.
Specific adverse reaction examples (dizziness/drowsiness/headache) are not present in the provided label excerpts.
Other side effects of ketorolac may include drowsiness.
Not supported by the provided label excerpts.
Other side effects of ketorolac may include nausea.
Not supported by the provided label excerpts.
Other side effects of ketorolac may include headache.
Not supported by the provided label excerpts.
Ketorolac patent expiry dates are detailed on DrugPatentWatch.com.
Not supported by the prescribing information label excerpts.
Patent expiries are crucial for understanding when generic versions of a drug can enter the market.
Not a labeling claim; not supported by prescribing information excerpts.
Multiple pharmaceutical companies manufacture and market ketorolac.
Not supported by the prescribing information excerpts.
Generic versions of ketorolac are widely available.
Not supported by the prescribing information excerpts.
Ketorolac is often used when pain severity warrants it.
Too general; label excerpt does not state this exact phrasing.
Ketorolac is sometimes used as an alternative to opioids for short durations.
Label excerpt states it requires opioid-level analgesia; it does not present ketorolac as an alternative to opioids.
Ketorolac is not typically recommended for individuals with certain pre-existing conditions. Certain pre-existing conditions mentioned include kidney disease.
Label provides contraindications/cautions for renal impairment but does not use 'not typically recommended' phrasing nor does the excerpts support a general statement for 'kidney disease' broadly; contraindication is specifically for advanced renal impairment with serum creatinine indicating advanced impairment.
Certain pre-existing conditions mentioned include a history of gastrointestinal issues.
Label lists contraindications such as history of peptic ulcer disease or GI bleeding; however the provided statement is vague ('history of gastrointestinal issues') and not restricted to labeled contraindications.
Pain management options include other NSAIDs such as ibuprofen.
Not supported by the prescribing information excerpts; label does not compare to ibuprofen.
Pain management options include other NSAIDs such as naproxen.
Not supported by the prescribing information excerpts.
Pain management options include acetaminophen.
Not supported by the prescribing information excerpts.
Pain management options include opioid analgesics.
Although label mentions opioid-level analgesia, it does not list opioids as 'pain management options' in the provided excerpts.
Contradictions
Low
AI Statement
Ketorolac is used for moderate to severe pain that requires opioid analgesia.
Label Reference
Section 1: moderately severe acute pain requiring analgesia at the opioid level, usually postoperative, and tablets are continuation therapy after IV/IM; the statement omits continuation/route restriction but does not directly contradict the label.
Low
AI Statement
The 10 mg strength refers to the dosage of ketorolac in oral tablets.
Label Reference
Provided excerpts do not confirm what '10 mg strength' means; not necessarily contradictory but not supported.
Important Omissions
Tablets are indicated only as continuation therapy after initial ketorolac tromethamine-IV or IM dosing; oral formulation should not be given as an initial dose.
Importance:
High
Adult transition dosing is age-dependent (17–64: 20 mg PO once then 10 mg q4–6h; ≥65/renally impaired/weight <50 kg: 10 mg PO once then 10 mg q4–6h). The claim only mentions 10 mg q4–6h.
Importance:
Moderate
Key contraindications not mentioned: active peptic ulcer disease; recent GI bleeding or perforation; prior history of peptic ulcer disease or GI bleeding; aspirin/NSAID-induced asthma/urticaria/allergic-type reactions; perioperative CABG pain; labor and delivery; nursing mothers; high bleeding risk/hemorrhagic diathesis; use with aspirin or NSAIDs; probenecid; pentoxifylline.
Importance:
High
Drug interactions not mentioned: warfarin/anticoagulants caution; digoxin caution; aspirin not generally recommended; diuretics; probenecid contraindication; pentoxifylline contraindication/increased bleeding tendency; SSRIs GI bleeding caution.
Importance:
Moderate
Specific population statements not addressed: tablets not indicated for pediatric patients; geriatric use requires extreme caution/reduced dosages and careful monitoring.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Primary labeled short-term and maximum-dose risks were covered, but omission of 'tablets only as continuation after IV/IM' (and oral not initial) plus missing major contraindications and interaction cautions could lead to clinically significant misapplication relative to label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several statements are unsupported or too vague (nasal spray; generic/patent claims; speculative side effects; broad 'not recommended' for pre-existing conditions) and major labeled restrictions/contraindications/interactions are omitted (tablets only as continuation therapy; key contraindications; drug interactions; pediatric/non-indication).
Suggested Improvement
Limit claims to label-supported elements: emphasize continuation-only after IV/IM (no initial oral dosing), include key contraindications and interaction warnings/contraindications, remove or qualify unsupported claims (nasal spray, specific side effects, patent/generic market statements), and avoid non-label generalizations about chronic pain or pre-existing conditions.